

Yinghong Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4860548/publications.pdf>

Version: 2024-02-01

65
papers

8,064
citations

361296

20
h-index

214721

47
g-index

67
all docs

67
docs citations

67
times ranked

7348
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1128-1155.	1.1	4
2	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 387-405.	2.3	124
3	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. <i>Hepatology Communications</i> , 2022, 6, 1776-1785.	2.0	7
4	AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. <i>Gastroenterology</i> , 2021, 160, 1384-1393.	0.6	121
5	Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. , 2021, 9, e002058.		30
6	Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors. <i>New England Journal of Medicine</i> , 2021, 384, 581-583.	13.9	53
7	Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 402-408.	0.6	7
8	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. <i>European Journal of Cancer</i> , 2021, 157, 140-152.	1.3	42
9	Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 700-708.	2.3	19
10	Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent <i>Clostridioides difficile</i> in cancer patients. <i>Journal of Cancer</i> , 2021, 12, 6498-6506.	1.2	6
11	Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1415-1424.	2.3	10
12	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 3978-3992.	0.8	121
13	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4126.	0.8	580
14	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. , 2021, 9, e003277.		49
15	Immunotherapy-Mediated Luminal Gastrointestinal Toxicities. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 331-337.	0.8	0
16	Rate of colorectal neoplasia in patients with Hodgkin lymphoma. <i>Colorectal Disease</i> , 2020, 22, 154-160.	0.7	2
17	Immune-checkpoint inhibitors induced diarrhea and colitis. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 25-32.	1.0	21
18	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	0.8	135

#	ARTICLE	IF	CITATIONS
19	Severe fistulizing pancreatitis in a patient with Merkel cell carcinoma treated with avelumab. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1266-1267.	0.8	5
20	Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726.		21
21	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. <i>Cancers</i> , 2020, 12, 1862.	1.7	47
22	Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. <i>Clinical Colorectal Cancer</i> , 2020, 19, e117-e123.	1.0	6
23	Checkpoint Inhibitor-Induced Colitis. <i>American Journal of Gastroenterology</i> , 2020, 115, 1301-1302.	0.2	2
24	Management of Immune-Related Colitis During the COVID-19 Pandemic. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e110-e111.	0.9	4
25	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
26	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. , 2020, 8, e000604.		98
27	Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. <i>JCO Oncology Practice</i> , 2020, 16, 453-461.	1.4	42
28	An Aggressive Approach Toward a Case of Refractory Ulcerative Colitis With Uncertain Etiology in the Context of Chronic Myeloid Leukemia. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e26-e27.	0.9	4
29	Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 797-799.	1.1	13
30	Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 662-668.	0.9	18
31	Reply to Y. Inagaki et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 1749-1750.	0.8	1
32	Patients with non-colorectal cancers may be at elevated risk of colorectal neoplasia. <i>Journal of Cancer</i> , 2020, 11, 3192-3198.	1.2	0
33	Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. <i>Annals of Oncology</i> , 2020, 31, 724-744.	0.6	129
34	Gastrointestinal Tract Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 247-253.	0.8	5
35	Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1432-1452.	1.9	28
36	Hepatobiliary Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 271-276.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. , 2019, 7, 242.		60
38	Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunology, Immunotherapy, 2019, 68, 553-561.	2.0	57
39	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. Journal of Clinical Oncology, 2019, 37, 2738-2745.	0.8	138
40	Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. , 2019, 7, 118.		26
41	Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scandinavian Journal of Gastroenterology, 2019, 54, 538-545.	0.6	51
42	Patients with Non-Hodgkinâ€™s Lymphoma Are at Risk of Adenomatous Colon Polyps. Digestive Diseases and Sciences, 2019, 64, 2965-2971.	1.1	1
43	Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitorâ€™induced colitis. , 2019, 7, 93.		131
44	Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. , 2019, 7, 31.		94
45	Clinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients. Current Gastroenterology Reports, 2019, 21, 8.	1.1	17
46	Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. , 2019, 7, 47.		22
47	Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 789-796.	0.6	12
48	Clinical Features of Rituximab-associated Gastrointestinal Toxicities. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 539-545.	0.6	19
49	Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?. Inflammatory Bowel Diseases, 2019, 25, 385-393.	0.9	63
50	Clinical characteristics of colitis induced by taxane-based chemotherapy. Annals of Gastroenterology, 2019, 33, 59-67.	0.4	12
51	Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment. Journal of Immunotherapy and Precision Oncology, 2019, 2, 40-45.	0.6	6
52	Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflammatory Bowel Diseases, 2018, 24, 1695-1705.	0.9	177
53	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1714-1768.	0.8	2,691
54	Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohnâ€™s disease of the pouch. Alimentary Pharmacology and Therapeutics, 2018, 48, 1251-1259.	1.9	6

#	ARTICLE	IF	CITATIONS
55	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. <i>Nature Medicine</i> , 2018, 24, 1804-1808.	15.2	521
56	Immune Checkpoint Inhibitors-Induced Colitis. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 151-157.	0.8	19
57	Immune Checkpoint Inhibitors-Induced Hepatitis. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 159-164.	0.8	26
58	Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. , 2018, 6, 142.		146
59	Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. , 2018, 6, 95.		146
60	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. , 2018, 6, 103.		130
61	Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. , 2018, 6, 37.		174
62	The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients's™ Outcomes. <i>Journal of Immunotherapy and Precision Oncology</i> , 2018, 1, 7-18.	0.6	40
63	Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. , 2017, 5, 95.		1,460
64	Efficacy and Safety of Vedolizumab and Infliximab Treatment for Immune-Mediated Diarrhea and Colitis in Cancer Patients: A Multi-Center Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
65	Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 0, , .	1.4	2